Literature DB >> 21573415

Evaluation of the cytotoxicity of the indoloquinone eo9 in a human colon adenocarcinoma model.

M Bibby, B Cronin, R Phillips.   

Abstract

The development of anti-cancer drugs that are active in regions of low oxygen tension within solid tumours is an important goal for the chemotherapist. Equally as important is the utilization of appropriate model systems for their selection. This study describes morphological characteristics of multicellular spheroids derived from the human carcinoma cell line, DLD-1 and the evaluation of an investigational bioreductive alkylating agent (EO9) in monolayers, spheroids and xenografts. Histological examination of the cell line in vitro revealed typical features of glandular epithelium with microvilli on free surfaces and cell junction formation. Spheroids had acina formation, extensive necrosis and hypoxia at the time of treatment suggesting the spheroid model to be more representative of solid tumour geometry than more conventional in vitro test systems. EO9 is active against this cell line grown as a monolayer (IC50=0.76 mug ml-1) but is inactive against spheroids or established solid tumours in vivo. The suitability of this system for evaluating bioreductive drugs is discussed.

Entities:  

Year:  1993        PMID: 21573415     DOI: 10.3892/ijo.3.4.661

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  3 in total

Review 1.  Emerging drug treatments for solid tumours.

Authors:  J H Schellens; L C Pronk; J Verweij
Journal:  Drugs       Date:  1996-01       Impact factor: 9.546

Review 2.  EO9 (Apaziquone): from the clinic to the laboratory and back again.

Authors:  Roger M Phillips; Hans R Hendriks; Godefridus J Peters
Journal:  Br J Pharmacol       Date:  2013-01       Impact factor: 8.739

3.  Pharmacological approach towards the development of indolequinone bioreductive drugs based on the clinically inactive agent EO9.

Authors:  P M Loadman; M C Bibby; R M Phillips
Journal:  Br J Pharmacol       Date:  2002-11       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.